Ranolazine sustained release tablets

A ranolazine, sustained-release technology, applied in non-active ingredients medical preparations, cardiovascular system diseases, organic active ingredients, etc., can solve the problems of unstable preparations, easy moisture absorption, large fluctuations, etc.

Inactive Publication Date: 2008-05-14
TIANJIN HANKANG PHARMA BIOTECH
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] According to the characteristics of ranolazine, it is best to prepare ranolazine into sustained-release preparations, but ranolazine is prepared into sustained-release preparations an

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ranolazine sustained release tablets
  • Ranolazine sustained release tablets
  • Ranolazine sustained release tablets

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0151] (1) Tablet core prescription

[0152] ranolazine

500g

hypromellose K4M

hypromellose 60RT5

lactose

10% povidone K30 absolute alcohol

Magnesium stearate

150g

100g

300g

Appropriate amount

20g

production

1000 pieces

[0153] (2) Prescription of coating solution

[0154] hypromellose 60RT5

Talc powder

Titanium dioxide

Polyethylene glycol 600

65g

20g

25g

10g

75% ethanol water

Add to 1000ml.

[0155] Preparation,

[0156] 1 smash

[0157] ranolazine, hypromellose K4M , hypromellose 60RT5 and lactose were respectively crushed through a 100-mesh sieve, and set aside.

[0158] 2. Weighing and mixing

[0159] The above-mentioned raw and auxiliary materials were weighed respectively according to the prescription amount and calculated by double checking.

[0160] 3. Granulation

[0161] Use 10% povidon...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a Reynolds pyrazine slow-released tablet, which is characterized in that the tablet comprises not more than 50wt% Reynolds pyrazine and at least an independent adhesive with 1-20wt% low viscosity PH and a or a plurality of independent adhesive with 1-20wt% high viscosity PH.

Description

Technical field: [0001] The invention relates to a new preparation of ranolazine, in particular to a sustained-release tablet of ranolazine. Background technique: [0002] Ranolazine, its chemical name is: N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide [0003] Its structural formula is: [0004] [0005] Partition formula: C 24 h 33 N 3 o 4 [0006] Molecular weight: 427.54 [0007] Pharmacological type: partial fatty acid oxidase inhibitor [0008] Mechanism of action: Ranolazine is a local lipoxygenase inhibitor, which can reduce the oxygen demand of the heart through enzyme regulation, improve the imbalance between oxygen supply and demand, and relieve the symptoms of local myocardial ischemia. In addition, ranolazine can also enhance the oxidation of glucose while reducing the oxidation of free fatty acids by regulating the body's metabolism, thereby increasing the oxygen utilization rate of the heart. [0009] Indicati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/22A61K9/36A61K31/495A61K47/38A61P9/10
Inventor 严洁
Owner TIANJIN HANKANG PHARMA BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap